Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial

Poster Session
Presenter: David R. Spigel, MD, FASCO
Abstract Number: 8511
Presented: June 4, 2021
Track: Lung Cancer
Disclosures: View Disclosures
© 2022 American Society of Clinical Oncology (ASCO®). All Rights Reserved.
Share:
Share on facebook
Share on twitter
Share on linkedin

Other Lung Cancer Content

Expert Interview

Lung Cancer – Expert Insights

Dr Goto shares discusses the safety and efficacy findings of the phase 1 clinical trial of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody-drug conjugate, in patients with advanced EGFR-mutant NSCLC (abstract 9007). He also highlights the results from the phase 3 IMPACT trial of adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with phase 2-3 EGFR-mutated NSCLC (abstract 8501).
Interviewee: Yasushi Goto, MD
Interview Date: June 11, 2021
Expert Interview

Lung Cancer – Expert Insights

Dr Sanborn shares her ASCO21 highlights for lung cancer focusing on the outcomes of the use of anti-PD-(L)1 therapy in combination with chemotherapy versus immunotherapy in patients with advanced NSCLC (abstract 9001), results from the phase II CodeBreak 100 trial of sotorasib in pretreated KRASG12C-mutated NSCLC (abstract 9003) and provides an update from the PACIFIC trial (abstract 8511).
Interviewee: Rachel Sanborn
Interview Date: June 10, 2021
Expert Interview

Lung Cancer – Expert Insights

Dr Wakelee discusses her ASCO21 highlights for lung cancer, including results from the phase III global IMpower010 study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLC (abstract 8500), findings from a pooled analysis of eight randomized controlled trials to evaluate the use of anti-PD(L1) therapy in combination with chemotherapy versus immunotherapy for 1L treatment of advanced NSCLC with PD-L1 score 1-49% (abstract 9001), and results of the OS and exploratory subgroup analyses from the phase 2 CodeBreak 100 trial evaluating sotorasib in pretreated KRAS p.G21c mutated NSCLC (abstract 9003).
Interviewee: Heather A. Wakelee, FASCO, MD
Interview Date: June 9, 2021
Expert Interview

Lung Cancer – Expert Insights

Dr Reck discusses his ASCO21 highlights on non-small cell lung cancer, including updates on nivolumab plus ipilimumab at 4 years from CheckMate 227 (abstract 9016) and at 2 years from CheckMate 9LA (abstract 9000), and phase 2 trial data from KEYNOTE-799 for the novel combination of pembrolizumab plus platinum chemotherapy and radiotherapy (abstract 8512).
Interviewee: Martin Reck, MD, PhD
Interview Date: June 7, 2021
Oral Abstract Session

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC)

Presenter: Heather A. Wakelee, FASCO, MD
Presentation Date: June 6, 2021
Abstract Number: 8500
Oral Abstract Session

Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial

Presenter: Hirohito Tada, MD
Presentation Date: June 6, 2021
Abstract Number: 8501
Oral Abstract Session

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA

Presenter: Martin Reck, MD, PhD
Presentation Date: June 4, 2021
Abstract Number: 9000
Oral Abstract Session

Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis

Presenter: Oladimeji Akinboro, MD, MPH
Presentation Date: June 4, 2021
Abstract Number: 9001
Oral Abstract Session

Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer

Presenter: Ferdinandos Skoulidis, MD, PhD
Presentation Date: June 4, 2021
Abstract Number: 9003
Oral Abstract Session

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)

Presenter: Pasi A. Janne, MD, PhD
Presentation Date: June 4, 2021
Abstract Number: 9007
We'd love your feedback!
We'd love your feedback!

Welcome to ASCO Direct™

2021 Annual Meeting Highlights

Expert insights into key ASCO21 data that will impact clinical practice and patient care plus complimentary access to 50 official ASCO video presentations and downloadable slides, picked by our Experts.

ASCO Direct is an officially licensed program of the American Society of Clinical Oncology® (ASCO®)

This program is supported by Bristol Myers Squibb and brought to you by Springer Healthcare